Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5557408 | 1.00 | TK2 (0.42) | TK2TK1 | |
| SCHEMBL24512779 | 1.00 | TK2 (0.42) | TK2TK1 | |
| SCHEMBL2769235 | 1.00 | TK2 (0.42) | TK2TK1 | |
| SCHEMBL3841357 | 0.94 | TK2 (0.40) | TK2TK1 | |
| SCHEMBL19305222 | 0.92 | TK2 (0.41) | TK2TK1 | |
| SCHEMBL2298778 | 0.91 | TK2 (0.42) | TK2TK1 | |
| SCHEMBL25630027 | 0.91 | TK2 (0.40) | TK2TK1 | |
| SCHEMBL2770802 | 0.88 | TK2 (0.40) | TK2TK1 | |
| SCHEMBL5558232 | 0.88 | TK2 (0.40) | TK2TK1 | |
| SCHEMBL24512780 | 0.88 | TK2 (0.38) | TK2TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728591-B1 | GAPMER OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE | ROCHE INNOVATION CT COPENHAGEN AS (DK) | 2025-07-23 | — | — | EP | disclosed |
| EP-3728590-B1 | NOVEL THIOPHOSPHORAMIDITES | ROCHE INNOVATION CT COPENHAGEN AS (DK) | 2025-07-02 | — | — | EP | disclosed |
| CN-111448316-B | Novel thiophosphorous acid amides | 罗氏创新中心哥本哈根有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20240368593-A1 | GAPMER OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2024-11-07 | — | — | US | disclosed |
| EP-3728592-B1 | OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE | ROCHE INNOVATION CT COPENHAGEN AS (DK) | 2024-05-29 | — | — | EP | disclosed |
| US-11597926-B2 | Thiophosphoramidites | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2023-03-07 | — | — | US | disclosed |
| US-11597926-B2 | Thiophosphoramidites | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2023-03-07 | — | — | US | disclosed |
| US-20230002762-A1 | OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2023-01-05 | — | — | US | disclosed |
| EP-4092117-A1 | GAPMER OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE | Roche Innovation Center Copenhagen A/S (DK) | 2022-11-23 | — | — | EP | disclosed |
| EP-4092118-A1 | NOVEL THIOPHOSPHORAMIDITES | Roche Innovation Center Copenhagen A/S (DK) | 2022-11-23 | — | — | EP | disclosed |
| EP-4074724-A1 | OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE | Roche Innovation Center Copenhagen A/S (DK) | 2022-10-19 | — | — | EP | disclosed |
| US-20220112493-A1 | PHOSPHONOACETATE GAPMER OLIGONUCLEOTIDES | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2022-04-14 | — | — | US | disclosed |
| US-20220073916-A1 | NOVEL PHOSPHORAMIDITES | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2022-03-10 | — | — | US | disclosed |
| US-20210115438-A1 | NOVEL THIOPHOSPHORAMIDITES | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2021-04-22 | — | — | US | disclosed |
| US-20210115438-A1 | NOVEL THIOPHOSPHORAMIDITES | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2021-04-22 | — | — | US | disclosed |
| US-20200339982-A1 | OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2020-10-29 | — | — | US | disclosed |
| US-20200339982-A1 | OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2020-10-29 | — | — | US | disclosed |
| US-20200332289-A1 | GAPMER OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2020-10-22 | — | — | US | disclosed |
| US-20070270370-A1 | Novel bicyclonucleoside analogues | SANKYO COMPANY, LIMITED (JP) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270370-A1 | Novel bicyclonucleoside analogues | PURB, RNGTT, NSUN2 | TK2 231/4885TK1 133/4885 |
| US-20230002762-A1 | OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE | DUT, TYMP, TYMS | TK2 76/4885TK1 26/4885 |
| US-20220073916-A1 | NOVEL PHOSPHORAMIDITES | P2RY11, P2RX5, P2RX2 | TK2 941/4885TK1 466/4885 |
| US-20200339982-A1 | OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE | DUT, TYMP, TYMS | TK2 59/4885TK1 34/4885 |
| US-20210115438-A1 | NOVEL THIOPHOSPHORAMIDITES | TYMP, RRM2B, RNGTT | TK2 146/4885TK1 123/4885 |
| US-11597926-B2 | Thiophosphoramidites | TYMP, RRM2B, RRM2 | TK2 163/4885TK1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.